Table 3.
Characteristics, management, and treatment outcomes for Hr-TB, RR/MDR-TB and pre-XDR-TB
| No. | Year | Age | Sex | U/D | Source person | Site | DST result | Regimen | Total duration of treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Newly diagnosed TB | ||||||||||
| 1 | 2013 | 4 | M | VUR | No | Pulmonary | Hr | 2HRZE/4HR/3ROfx | 9 months | Complete |
| 2 | 2014 | 3 | M | No | No | Disseminated | Hr | 2HRZE/4RZEOf/9ROfx | 15 months | Complete |
| 3 | 2015 | 14 | M | HIV | No | Pulmonary and lymph node | Hr (InhA) | 2RZEOfx/4REOfx | 6 months | Complete |
| 4 | 2015 | 14 | M | No | No | Pulmonary and central nervous system | Hr (KatG) | 2RZEOfx/10REOfx | 12 months | Complete |
| 5 | 2015 | 0.1 | F | No | Mother | Pulmonary | RR (rpoB) | HRZE | 2 months | LTFU |
| 6 | 2015 | 0.4 | M | No | No | Pulmonary | Pre-XDR (KatG, rpoB, FQ) | Ethio,Z, Lfx,CS,PAS, Km | 18 months | Complete |
| 7 | 2016 | 0.2 | M | No | Mother | Congenital TB | Hr (InhA) | 1EAmOfx/3RZEOf/8RE | 12 months | Cured |
| 8 | 2016 | 5 | M | Down syndrome | No | Pulmonary | Hr (KatG) | 2RZELfx/4RLfx | 6 months | Complete |
| 9 | 2016 | 14 | M | No | No | Pulmonary and pleura | Hr (KatG) | RZE | 6 months | Complete |
| 10 | 2018 | 8 | F | Down syndrome | No | Disseminated | Hr | RZELfx | 12 months | Complete |
| 11 | 2019 | 2 | F | No | No | Miliary | Hr (KatG) | 12HRZELfx | 12 months | Complete |
| 12 | 2019 | 4 | M | No | Father | Osteoarticular | Hr (KatG) | 12RZELfx | 12 months | Complete |
| 13 | 2019 | 11 | F | No | Mother | Pulmonary | Hr (KatG) | 6RZELfx | 6 months | Complete |
| 14 | 2019 | 8 | F | Down syndrome | Father | Pulmonary and lymph node | Hr | 2HRZE/6RZE | 8 months | Complete |
| 15 | 2019 | 3 | M | No | No | Lymph node | Hr (InhA) | 3HRZE/4HR/6RZELfx | 13 months | Complete |
| 16 | 2020 | 14 | F | No | No | Pleura | Hr | 6RZELfx | 6 months | Complete |
| 17 | 2020 | 12 | F | No | No | Lymph node | RR (rpoB) | Shorter regimen (Bdq,Pto,Cfx,Lfx,H,Z,E) | 4 months | LTFU |
| 18 | 2020 | 10 | F | No | No | Pulmonary and lymph node | Hr (KatG) | 6RZELfx | 6 months | Complete |
| 19 | 2020 | 13 | F | No | Father | Pulmonary | Pre-XDR (FQ) | Bdq,LZ,Cfz,Cs,Am,Eto | 18 months | Complete |
| History of previous TB treatment | ||||||||||
| 1 | 2006 | 10 | F | No | No | Pulmonary | MDR, Strep | EKmLfxCsPAS | 18 | Complete |
| 2 | 2008 | 10 | M | HIV | No | Pulmonary | MDR, Strep | HRZE | – | Died |
VUR = vesicoureteral reflux; HIV = human immunodeficiency virus infection; Hr-TB = isoniazid-resistant tuberculosis; RR-TB = rifampicin-resistant tuberculosis; MDR-TB = multidrug-resistant tuberculosis; pre-XDR-TB = pre-extensively drug-resistant tuberculosis; U/D = underlying disease; LTBI = latent TB infection; DST = drug susceptibility test; H =isoniazid; R = rifampicin; Z = pyrazinamide; E = ethambutol; FQ = fluoroquinolone; Ofx = ofloxacin; Lfx = levofloxacin; Bdq = bedaquiline; LZ = linezolid; Cfz = clofazamine; Cs = cycloserine; Am = amikacin; Km = kanamycin; Eto = ethionamide; Pto = prothionamide; PAS = para aminosalicylic acid; LTFU = lost to follow-up